GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Next Science Ltd (ASX:NXS) » Definitions » EV-to-EBITDA

Next Science (ASX:NXS) EV-to-EBITDA : -3.01 (As of Jun. 07, 2024)


View and export this data going back to 2019. Start your Free Trial

What is Next Science EV-to-EBITDA?

EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Next Science's enterprise value is A$64.79 Mil. Next Science's EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 was A$-21.52 Mil. Therefore, Next Science's EV-to-EBITDA for today is -3.01.

The historical rank and industry rank for Next Science's EV-to-EBITDA or its related term are showing as below:

ASX:NXS' s EV-to-EBITDA Range Over the Past 10 Years
Min: -24.91   Med: -11.12   Max: -1.99
Current: -3.01

During the past 6 years, the highest EV-to-EBITDA of Next Science was -1.99. The lowest was -24.91. And the median was -11.12.

ASX:NXS's EV-to-EBITDA is ranked worse than
100% of 712 companies
in the Drug Manufacturers industry
Industry Median: 14.135 vs ASX:NXS: -3.01

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

As of today (2024-06-07), Next Science's stock price is A$0.265. Next Science's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was A$-0.104. Therefore, Next Science's PE Ratio for today is At Loss.

The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio.


Next Science EV-to-EBITDA Historical Data

The historical data trend for Next Science's EV-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Next Science EV-to-EBITDA Chart

Next Science Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EV-to-EBITDA
Get a 7-Day Free Trial -18.55 -14.18 -17.61 -7.51 -4.03

Next Science Semi-Annual Data
Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
EV-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only -17.61 - -7.51 - -4.03

Competitive Comparison of Next Science's EV-to-EBITDA

For the Drug Manufacturers - Specialty & Generic subindustry, Next Science's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Next Science's EV-to-EBITDA Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Next Science's EV-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Next Science's EV-to-EBITDA falls into.



Next Science EV-to-EBITDA Calculation

Next Science's EV-to-EBITDA for today is calculated as:

EV-to-EBITDA=Enterprise Value (Today)/EBITDA (TTM)
=64.788/-21.515
=-3.01

Next Science's current Enterprise Value is A$64.79 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Next Science's EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 was A$-21.52 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Next Science  (ASX:NXS) EV-to-EBITDA Explanation

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

Next Science's PE Ratio for today is calculated as:

PE Ratio=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=0.265/-0.104
=At Loss

Next Science's share price for today is A$0.265.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Next Science's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was A$-0.104.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio.

Please read Which price ratio outperforms the enterprise multiple?


Next Science EV-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Next Science's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


Next Science (ASX:NXS) Business Description

Traded in Other Exchanges
Address
821 Pacific Highway, Suite 1902, Level 19, Tower A, The Zenith Building, Chatswood, NSW, AUS, 2067
Next Science Ltd is a medical technology company. It is engaged in the development and commercialization of its proprietary Xbio technology to reduce the impact of biofilm-based infections in human health. Xbio is a non-toxic technology with proven efficacy in eradicating both biofilm based and free-floating bacteria. Its products include Bactisure, SURGX, XEPERIENCE and BLASTX. The company derives revenue from the U.S. and Australia, of which prime revenue is derived from the U.S.

Next Science (ASX:NXS) Headlines

No Headlines